2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights

• Main Authors: Mostafa M. Elbadawi (Author), Wagdy M. Eldehna (Author), Amer Ali Abd El-Hafeez (Author), Warda R. Somaa (Author), Amgad Albohy (Author), Sara T. Al-Rashood (Author), Keli K. Agama (Author), Eslam B. Elkaeed (Author), Pradipta Ghosh (Author), Yves Pommier (Author), Manabu Abe (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In this study, different assortments of 2-arylquinolines and 2,6-diarylquinolines have been developed. Recently, we have developed a new series of 6,7-dimethoxy-4-alkoxy-2-arylquinolines as Topoisomerase I (TOP1) inhibitors with potent anticancer activity. Utilising the SAR outputs from this study,...